Moderate Evidence Research Overview

Melanotan II Research for Tanning

An evidence-based overview of research examining Melanotan II in the context of tanning. This page synthesizes findings from peer-reviewed literature.

Research Summary

Melanotan II stimulates melanogenesis through melanocortin-1 receptor activation, producing skin darkening without UV exposure. The peptide was originally developed by University of Arizona researchers as a potential skin cancer prevention agent. The tanning effect occurs through increased melanin production in melanocytes. Users can develop significant skin darkening, particularly with initial 'loading' doses. Melanotan II is not approved by any regulatory agency. Concerns include effects on existing moles/nevi, potential for melanoma masking or promotion, and lack of quality control in unregulated products.

Referenced Studies

Click any PMID to view the full study on PubMed.

Other Peptides Studied for Tanning

Important Disclaimer

This page summarizes research findings and does not constitute medical advice. Melanotan II may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.